Many important natural products are produced by non-ribosomal peptide synthetases 
Introduction
Secondary metabolite derived drugs have become essential agents to cure infectious diseases during the last almost 70 years 3, 4 . Yet, infectious diseases are still the second major cause of death worldwide and furthermore, the world is facing a global public-health crisis as there is a growing risk of re-entering a pre-antibiotic era, since more and more infections are caused by multi-drug-resistant bacteria 5 .
One source of new antibacterial agents are non-ribosomally made peptides (NRPs).
Their high structural diversity imparts to them many properties of biological relevance and peptides have been identified with antibiotic, antiviral, anti-cancer, antiinflammatory, immunosuppressant and surfactant qualities 6, 7, 8 . However, natural products often need to be modified to improve clinical properties and/or bypass resistance mechanisms 9, 10 . To date, most clinically used NP derivatives are created by means of semi-synthesis 9, 11 . A promising alternative strategy is the use of engineering approaches to modify NRP producing non-ribosomal peptide synthetase (NRPS) directly in order to produce optimized or non-natural natural products 12 .
However, to date most attempts to achieve this have yielded impaired or nonfunctional biosynthetic machineries 7, 13 .
NRPSs are large multienzyme complexes (megasynthases) 14 that form peptides not limited to the twenty proteinogenic amino acids (AA) 15 . Furthermore, these NRPS can generate linear or cyclic peptides containing D-AA, N-methylated AA, N-terminal attached fatty acids (FA) or heterocycles 1, 2, 14, 15 . NRPS do this by exhibiting a strict modular architecture in which a module is defined as the catalytic unit responsible for the incorporation of one specific building block (e.g. AA) into the growing peptide chain (N → C) and associated functional group modifications 16 . Modules are composed of domains that catalyze the single reaction steps like activation, covalent binding, optional modification of the building blocks, and condensation with the amino acyl or peptidyl group on the neighboring module 17 . At least three domains or essential enzymatic activities, respectively, are necessary for the non-ribosomal production of peptides (Fig. 1) . They reside in the adenylation (A) for AA activation, thiolation (T) for AA tethering, and condensation (C) domains for peptide bond formation. Finally, most NRPS termination modules harbor a TE domain that releases the peptide, often in a cyclized form. These standard domains are additionally joined by tailoring domains that can catalyze epimerization (E), methylation (MT), cyclization (CY) or other modifications of the building blocks or the growing peptide chain . However, with exception of the latter and recently published strategy, denoted as the concept of eXchange Units (XU) 22 , it has been difficult to develop clearly defined, reproducible and validated guidelines for engineering modified NRPS.
The limitation of the XU-concept is that the natural downstream C domain specificity must be obeyed clearly restricting its applicability and the C-domain specificities have to be met -at the donor as well as at the acceptor site. This disadvantage can be accepted if a large number of XUs with different downstream C domains are available. Due to these limitations also at least two XUs have to be exchanged to produce a new peptide derivative that differs in one AA position from the primary sequence of the wild type (WT) peptide 22 . However, a more flexible system reducing the limitations of C-domain specificities would drastically reduce the amount of NRPS building blocks necessary to produce or alter particular peptides and would enable the creation of artificial natural product libraries with hundreds or thousands of entities for large scale bioactivity screenings.
Results and Discussion
C-domains have acceptor site substrate specificity
To verify the influence of the C-domains acceptor site (CAsub) proof reading activity, the GameXPeptide producing NRPS GxpS of Photorhabdus luminescens TT01
(Supplementary Figure 1 and 2) was chosen as a model system 23, 24 . A recombinant GxpS was constructed, not complying with the C-domain specificity rules of the XU concept 22 . Here, XU2 of GxpS (Fig. 1b , NRPS-1) was exchanged against XU2 of the bicornutin producing NRPS (BicA, Fig. 1c ) 25 . Although both XUs are Leu specific, they are differentiated by their CAsub specificities -Phe for XU2 of GxpS and Arg for XU2 of BicA. Therefore, no peptide production was observed as expected. This experiment confirmed previously published scientific results from in vitro experiments [26] [27] [28] [29] , and illustrates that C domains indeed are highly substrate specific at their CAsub.
From the available structural data of C domains it is clear that they show a pseudodimer configuration 28, [30] [31] [32] with their catalytic center, including the HHXXXDG motif, having two binding sites -one for the electrophilic donor substrate and one for the nucleophilic acceptor substrate 29 ( Fig. 1a and Supplementary Figure 3 ). Therefore we concluded that the four AA long conformationally flexible loop/linker between both subdomains might be the ideal target to reconfigure C domain specificities via the engineering of C domain hybrids ( , it may be deduced from these results that C/E and C-domains cannot be combined with each other. Although NRPS-4 ( Fig. 2a) showed moderately reduced production titers, most likely due to the non-natural
CDsub-CAsub pseudo-dimer interface, the formal exchange of the promiscous XU2.01
from GxpS (for Val/Leu) against the Val-specific XU2.01 from XtpS led to exclusive production of 1 and 3 ( Fig. 2a) without production of 2 and 4 observed in the original GxpS (Fig. 1b) , indicating that the XU2.0 can also be used to increase product specificity and to reduce the formation of side products.
Additional GameXPeptide derivatives were generated ( Amending the starter unit
Up to date there is no publication describing the successful exchange of a starter unit against an internal NRPS-fragment. Reasons for that might be that (I) starter-Adomains in general comprise some kind of upstream sequence of variable length with unknown function and structure, which makes it difficult to define an appropriate artificial leader sequence, and that (II) necessary interactions at the C-A interface may be important for adenylation activity and A-domain stability as indicated recently 36, 37 . In order to test whether the XU2.0 concept can also be applied to modify starter units, three recombinant GxpS constructs (NRPS-7 -9) with internal domains as starting units were created (Fig. 2c) . In NRPS-7 A1-T1-CDsub2 of GxpS was Whereas NRPS-7 (Fig. 2c) did not show production of the desired peptides, NRPS-8
and NRPS-9 synthesized 1 and 3 in yields between 0.31-0.44 mg/L (Fig. 2c,   Supplementary Figure 9 ). This indicates that internal A-domains can indeed be used as starter domains, if the upstream CAsub or C-domain is kept in front of the A-domain pointing to the importance of a functional C-A interface for A-domain activity. Yet, the observed low production titers might indicate that for example the observed difference in codon usage and the lower GC-content at the beginning of WT NRPS encoding genes could have a major impact on transcriptional and/or translational efficiency in conjunction with protein folding as described previously 39, 40 .
Production of functionalized peptides
Besides simply creating NRP derivatives, one useful application of NRPS reprogramming is the incorporation of non-proteinogenic or even non-natural AA.
Examples for the latter might be AAs containing alkyne or azide groups, allowing reactions like Cu(I)-catalyzed or strain-promoted Huisgen cyclization also known as "click" reactions 41, 42, [42] [43] [44] . Yet, although NPRS and A domains have been examined exhaustively for several years, no general method for the in vivo functionalization of NRPs are available by reprogramming NRPS templates.
A broad range of AAs are accepted by the A3 domain of GxpS (Supplementary Figure 10) resulting in a large diversity of natural GameXPeptides 23, 24 . Moreover, by using a ɣ- Leu is the original substrate downstream of the introduced XU2.03 of GxpS (Fig. 1b) in its natural context, indicating that the overall structure of C domains along with resulting transformed C-A interface interactions might influence the A domain substrate specificity. Recently, similar but in vitro observed effects were reported regarding A domains from sulfazecin 36 and microcystin 37 . This effect could also be used to increase the specificity of A domains to prevent the formation of side products. Further investigations will shed light on this remarkable and yet unreported effect.
Production of peptide libraries
Modern drug-discovery approaches often apply the screening of compound libraries including NP libraries 48 since they exhibit a wide range of pharmacophores, structural diversity and have the property of metabolite-likeness often providing a high degree of bioavailability. Yet, the NP discovery process is as expensive as time consuming 49 .
Consequently, for bioactivity screenings the random recombination of certain NRPS fragments would be a powerful tool to create focused artificial NP-like libraries.
In an initial test, GxpS was chosen for the generation of a focused peptide library created via a one-shot yeast based TAR cloning approach 38, 50 . Here, the third position of the peptide (D-Phe) was randomized ( Figure 14) .
For the generation of a second and structurally more diverse peptide library, positions 1 (D-Val) and 3 (D-Phe) of GxpS were selected in parallel for randomization (Fig. 4b) . whereas 800 building blocks would be necessary to generate the same number of peptides using the XU concept. Consequently, the introduction of the XU2.0 simplifies and broadens the possibilities of biotechnological applications with respect to optimize bioactive agents via NRPS engineering exemplified for the reprogramming of NRPSs ( Fig. 1 and 2 ) or the production of functionalized peptides by incorporating XU2.0 building blocks accepting non-natural AAs like pN3-F and ¥-Y (Fig. 3 , Supplementary Figure 9 ) allowing further derivatization 41, 42, 53 .
However, the true strength of the XU2.0 concept is its application to generate random NP-like peptide libraries ( 
